375 related articles for article (PubMed ID: 17711302)
1. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.
Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
Biochemistry; 2007 Sep; 46(37):10713-21. PubMed ID: 17711302
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
[TBL] [Abstract][Full Text] [Related]
3. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.
Chroni A; Kan HY; Kypreos KE; Gorshkova IN; Shkodrani A; Zannis VI
Biochemistry; 2004 Aug; 43(32):10442-57. PubMed ID: 15301543
[TBL] [Abstract][Full Text] [Related]
4. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency.
Chroni A; Duka A; Kan HY; Liu T; Zannis VI
Biochemistry; 2005 Nov; 44(43):14353-66. PubMed ID: 16245952
[TBL] [Abstract][Full Text] [Related]
5. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.
Kypreos KE; Zannis VI
Biochem J; 2007 Apr; 403(2):359-67. PubMed ID: 17206937
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Natural LCAT Mutations on the Biogenesis of HDL.
Fotakis P; Kuivenhoven JA; Dafnis E; Kardassis D; Zannis VI
Biochemistry; 2015 Jun; 54(21):3348-59. PubMed ID: 25948084
[TBL] [Abstract][Full Text] [Related]
7. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo.
Chroni A; Koukos G; Duka A; Zannis VI
Biochemistry; 2007 May; 46(19):5697-708. PubMed ID: 17447731
[TBL] [Abstract][Full Text] [Related]
8. Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice.
Chroni A; Kan HY; Shkodrani A; Liu T; Zannis VI
Biochemistry; 2005 Mar; 44(10):4108-17. PubMed ID: 15751988
[TBL] [Abstract][Full Text] [Related]
9. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes.
Francone OL; Royer L; Haghpassand M
J Lipid Res; 1996 Jun; 37(6):1268-77. PubMed ID: 8808761
[TBL] [Abstract][Full Text] [Related]
10. In vivo studies of HDL assembly and metabolism using adenovirus-mediated transfer of ApoA-I mutants in ApoA-I-deficient mice.
Reardon CA; Kan HY; Cabana V; Blachowicz L; Lukens JR; Wu Q; Liadaki K; Getz GS; Zannis VI
Biochemistry; 2001 Nov; 40(45):13670-80. PubMed ID: 11695916
[TBL] [Abstract][Full Text] [Related]
11. Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders.
Daniil G; Phedonos AA; Holleboom AG; Motazacker MM; Argyri L; Kuivenhoven JA; Chroni A
Clin Chim Acta; 2011 Jun; 412(13-14):1213-20. PubMed ID: 21420943
[TBL] [Abstract][Full Text] [Related]
12. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal globular domain and the first class A amphipathic helix of apolipoprotein A-I are important for lecithin:cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo.
Scott BR; McManus DC; Franklin V; McKenzie AG; Neville T; Sparks DL; Marcel YL
J Biol Chem; 2001 Dec; 276(52):48716-24. PubMed ID: 11602583
[TBL] [Abstract][Full Text] [Related]
14. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.
Zannis VI; Chroni A; Krieger M
J Mol Med (Berl); 2006 Apr; 84(4):276-94. PubMed ID: 16501936
[TBL] [Abstract][Full Text] [Related]
15. An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.
Chen X; Burton C; Song X; McNamara L; Langella A; Cianetti S; Chang CH; Wang J
Int J Biol Sci; 2009 Jul; 5(5):489-99. PubMed ID: 19680471
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.
Miettinen HE; Jauhiainen M; Gylling H; Ehnholm S; Palomäki A; Miettinen TA; Kontula K
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3021-32. PubMed ID: 9409289
[TBL] [Abstract][Full Text] [Related]
17. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models.
Zannis VI; Koukos G; Drosatos K; Vezeridis A; Zanni EE; Kypreos KE; Chroni A
Ann Med; 2008; 40 Suppl 1():14-28. PubMed ID: 18246469
[TBL] [Abstract][Full Text] [Related]
18. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding.
Minnich A; Collet X; Roghani A; Cladaras C; Hamilton RL; Fielding CJ; Zannis VI
J Biol Chem; 1992 Aug; 267(23):16553-60. PubMed ID: 1644835
[TBL] [Abstract][Full Text] [Related]
19. Arginine 123 of apolipoprotein A-I is essential for lecithin:cholesterol acyltransferase activity.
Gorshkova IN; Mei X; Atkinson D
J Lipid Res; 2018 Feb; 59(2):348-356. PubMed ID: 29208698
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism.
Karuna R; Holleboom AG; Motazacker MM; Kuivenhoven JA; Frikke-Schmidt R; Tybjaerg-Hansen A; Georgopoulos S; van Eck M; van Berkel TJ; von Eckardstein A; Rentsch KM
Atherosclerosis; 2011 Feb; 214(2):448-55. PubMed ID: 21130455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
